|
Quotes & Info
|
| ANX > SEC Filings for ANX > Form 8-K on 26-Oct-2012 | All Recent SEC Filings |
26-Oct-2012
Other Events, Financial Statements and Exhibits
On October 25, 2012, ADVENTRX Pharmaceuticals, Inc. issued a press release announcing details of its planned phase 3 clinical study of ANX-188 (purified poloxamer 188) in sickle cell disease. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(d) Exhibits.
The list of exhibits called for by this Item is incorporated by reference to the Exhibit Index filed with this report.
|
|